Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NYSE MKT | Common Stock
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease.
AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation.
The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.
AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 16, 24 | -0.12 Decreased by -50.00% | -0.11 Decreased by -9.09% |
| Apr 2, 24 | -0.12 Decreased by -33.33% | -0.11 Decreased by -9.09% |
| Nov 15, 23 | -0.16 Decreased by -23.08% | -0.11 Decreased by -45.45% |
| Aug 15, 23 | -0.10 Increased by 0.00% | -0.11 Increased by +9.09% |
| May 15, 23 | -0.08 Increased by 0.00% | -0.11 Increased by +27.27% |
| Mar 16, 23 | -0.09 Increased by +25.00% | -0.12 Increased by +25.00% |
| Nov 15, 22 | -0.13 Decreased by -62.50% | -0.08 Decreased by -62.50% |
| Aug 15, 22 | -0.10 Increased by +16.67% | -0.07 Decreased by -42.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Apr 30, 24 | 40.00 K Decreased by -18.37% | -5.82 M Decreased by -104.32% | Decreased by -14.54 K% Decreased by -150.29% |
| Jan 31, 24 | 65.00 K Increased by +16.07% | -12.58 M Decreased by -192.74% | Decreased by -19.35 K% Decreased by -152.20% |
| Oct 31, 23 | 46.00 K Increased by +119.05% | -7.82 M Decreased by -25.08% | Decreased by -16.99 K% Increased by +42.90% |
| Jul 31, 23 | 42.00 K Increased by +40.00% | -4.91 M Increased by +1.96% | Decreased by -11.69 K% Increased by +29.97% |
| Apr 30, 23 | 49.00 K Increased by +48.48% | -2.85 M Increased by +36.56% | Decreased by -5.81 K% Increased by +57.28% |
| Jan 31, 23 | 56.00 K Increased by +12.00% | -4.30 M Increased by +26.51% | Decreased by -7.67 K% Increased by +34.39% |
| Oct 31, 22 | 21.00 K Decreased by -36.36% | -6.25 M Decreased by -63.33% | Decreased by -29.76 K% Decreased by -156.66% |
| Jul 31, 22 | 30.00 K Increased by +30.43% | -5.01 M Increased by +14.79% | Decreased by -16.69 K% Increased by +34.67% |